Trailing twelve months where a flow is involved, latest reported balance where it is not.
TRIKAFTAKAFTRIO is 86% of revenue.
Year to Dec 31, 2025 · $12B
Year to Dec 31, 2025 · $12B
Both on one scale, because both are money — the bar that is taller is the one that matters.
Cash counts short-term investments, not just the bank balance — technology companies park most of it in marketable securities, and leaving those out understates it several times over. Debt includes lease obligations.
Only the three costs filers report consistently. Anything a company does not break out sits outside these bands, so the stack is not the whole cost base.
Not on the overview because five charts is as much as one decision needs — but here in full, on one period switch. Each bar sums the four quarters ending there — a full year, brought up to today.
$12.95BQ3 2026+2.9%
Everything the company sold, before any costs. Each bar sums the four quarters ending there — a full year, brought up to today.
$4.54BQ3 2026-9.2%
Operating profit before depreciation and amortisation — approximated from operating income, because no depreciation tag is reported consistently enough across filers to do better. Treat it as indicative. Each bar sums the four quarters ending there — a full year, brought up to today.
$3.98BQ3 2026-9.7%30.7% of revenue
What was left after every cost, including tax. Each bar sums the four quarters ending there — a full year, brought up to today.
30.7%Q3 2026-12.3%
How much of every dollar of sales the company keeps as profit. A grocer keeps a few cents; a software company can keep half. Each point covers the four quarters ending there — a full year, brought up to today.
$3.2BQ3 2026-15.6%
Cash left over after running and maintaining the business. Each bar sums the four quarters ending there — a full year, brought up to today.
$15.53Q3 2026-9.6%
The same profit, split across every share. If this lags the profit chart above, the company is issuing shares and your slice is getting smaller. Restated onto today’s share count, so stock splits do not show as jumps. Each bar sums the four quarters ending there — a full year, brought up to today.
255.73MQ3 2026-0.2%
How many shares the profit is divided across. Rising is dilution; falling is the company buying itself back. Restated onto today’s basis, so splits do not show as jumps. Each point covers the four quarters ending there — a full year, brought up to today.
30.4xQ3 2026+3.2%
30.4x today · median 27.7x and range 18.7x–32.4x across the points shown, Q4 2020 to Q3 2026 The break in the line covers 4 periods with no meaningful multiple — a loss, or earnings so small the ratio says more about the denominator than the price.
Paid per unit of yearly profit. Periods with a loss, or profits too small for the ratio to mean anything, are left out — the line breaks rather than drawing through them. Each point covers the four quarters ending there — a full year, brought up to today.
Everything above comes from Vertex Pharmaceuticals Inc.’s own filings with the SEC, as reported. No estimates, no analyst figures, nothing adjusted.
Not reported by this filer: Gross Profit, Interest Income, Non-interest Income, Non-interest Expense, Provision for Credit Losses, Deposits, Loans, Short-term Borrowings, Borrowings (total), Dividends paid, Change in Payables and Accruals, Change in Other Operating Capital, and Change in Working Capital. Companies choose which XBRL tags to use, and anything untagged cannot be recovered — so these are blank rather than guessed.
$538.53-0.8%Nov 13 close
Figures through September 30, 2026, from the 10-Q filed November 3, 2026
Vertex develops and sells medicines for cystic fibrosis, inherited blood disorders, acute pain, and other serious diseases.
Company outlook: revenue of $13.2B to $13.3B for Fiscal year 2026 — up 10.0% on a year earlier